7 Biotech and Health Care Stocks to Buy

Theres more to health care than just cold and flu season. Making up the
pharmaceutical industry are biotechnology companies that do research and
development on medicines for serious illnesses, manufacture ways to treat
various diseases and are involved in everything from neurology to hematology.
Adding a little health care to your portfolio is a must because the baby boomer
generation will be relying on it in historical quantities in the coming years
the health care industry is expected to grow by an average of 5.8% per year
through 2020 . I watch more than 5,000 publicly traded companies with my
Portfolio Grader tool, ranking companies by a number of fundamental and
quantitative measures. And this week, Ive got seven biotech and health care
stocks to buy. Here they are, in alphabetical order. Each one of these stocks
gets an "A" or "B" according to my research, meaning it is a "strong
buy" or "buy." Alexion Pharmaceuticals (NASDAQ: ALXN ) is involved with
hematology, nephrology, neurology, ophthalmology and cancer treatments. Since
the start of 2011, ALXN stock is up 78%, compared to a gain of just 6% for the
Dow Jones. ALXN stock gets an "A" for sales growth, an "A" for earnings
growth, an "A" for earnings momentum, an "A" for its ability to exceed
the consensus earnings estimates on Wall Street, an "A" for the magnitude in
which earnings projections have increased during the past month and a "B"
for return on equity in my Portfolio Grader tool. For more information, view my
complete analysis of ALXN stock . Amgen (NASDAQ: AMGN ) discovers, develops,
manufactures and markets medicines for serious illnesses. AMGN stock has gained
17% year-to-date. AMGN stock gets a "B" for its ability to exceed the
consensus earnings estimates on Wall Street, a "B" for the magnitude in
which earnings projections have increased during the past month, a "B" for
cash flow and a "B" for return on equity in my Portfolio Grader tool. For
more information, view my complete analysis of AMGN stock . Biogen Idec (NASDAQ:
BIIB ) develops treatments for neurological disorders and other serious
diseases. Since the start of 2011, BIIB stock has jumped 66%. BIIB stock gets a
"B" for earnings growth, a "B" for earnings momentum, a "B" for cash
flow and an "A" for return on equity in my Portfolio Grader tool. For more
information, view my complete analysis of BIIB stock . Celgene (NASDAQ: CELG )
is a globally integrated biopharmaceutical company. In the past 12 months, CELG
stock has outpaced the broader markets with a gain of 15%. CELG stock gets an
"A" for sales growth, an "A" for earnings momentum, a "B" for
earnings growth, an "A" for the magnitude in which earnings projections have
increased during the past month, a "B" for cash flow and an "A" for
return on equity in my Portfolio Grader tool. For more information, view my
complete analysis of CELG stock . Gilead Sciences (NASDAQ: GILD ) is another
biopharmaceutical company worth mentioning, with its 10% return year-to-date.
GILD gets a "B" for earnings momentum, an "A" for cash flow and an
"A" for return on equity in my Portfolio Grader tool. For more information,
view my complete analysis of GILD stock . Pharmasset Inc. (NASDAQ: VRUS ) is a
clinical-stage pharmaceutical company and the big winner on this list. VRUS has
posted an astronomical gain of almost 470% in 2011. VRUS gets a "B" for
earnings momentum in my Portfolio Grader tool. For more information, view my
complete analysis of VRUS stock . Regeneron Pharmaceuticals Inc. (NASDAQ: REGN )
is involved with the discovery, development and commercialization of
pharmaceutical products for the treatment of serious medical conditions. REGN
rounds out the list with a gain of 70% year-to-date. REGN gets an "A" for
the magnitude in which earnings projections have increased during the past month
in my Portfolio Grader tool. For more information, view my complete analysis of
REGN stock . Get more analysis of these picks and other publicly traded stocks
with Louis Navellier's Portfolio Grader tool, a 100% free stock-rating tool
that measures both quantitative buying pressure and eight fundamental factors.